TY - JOUR
T1 - Cost-effectiveness of evidence-based pharmacotherapy or cognitive behavior therapy compared with community referral for major depression in predominantly low-income minority women
AU - Revicki, Dennis A.
AU - Siddique, Juned
AU - Frank, Lori
AU - Chung, Joyce Y.
AU - Green, Bonnie L.
AU - Krupnick, Janice
AU - Prasad, Manishi
AU - Miranda, Jeanne
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2005/8
Y1 - 2005/8
N2 - Background: Few clinical trials have evaluated interventions for major depressive disorder in samples of low-income minority women, and little is known about the cost-effectiveness of depression interventions for this population. Objective: To evaluate the cost-effectiveness of pharmacotherapy or cognitive behavior therapy (CBT) compared with community referral for major depression in low-income minority women. Design, Setting, and Participants: A randomized clinical trial was conducted in 267 women with current major depression. Interventions: Participants were randomly assigned to pharmacotherapy (paroxetine hydrochloride or bupropion hydrochloride) (n=88), CBT (n=90), or community referral (n=89). Main Outcome Measures: The main outcomes were intervention and health care costs, depression-free days, and quality-adjusted life years based on Hamilton Depression Rating Scale scores and Medical Outcomes Study 36-Item Short-Form Health Survey summary scores for 12 months. Cost-effectiveness ratios were estimated to compare incremental patient outcomes with incremental costs for pharmacotherapy relative to community referral and for CBT relative to community referral. Results: Compared with the community referral group, the pharmacotherapy group had significantly lower adjusted mean Hamilton Depression Rating Scale scores from the 3rd month through the 10th month (P=.04 to P<.001) of the study, and the CBT group had significantly lower adjusted mean scores from the 5th month through the 10th month (P=.03 to P=.049). There were significantly more depression-free days in the pharmacotherapy group (mean, 39.7; 95% confidence interval, 12.9-66.5) and the CBT group (mean, 25.80; 95% confidence interval, 0.04-51.50) than in the community referral group. The cost per additional depression-free day was $24.65 for pharmacotherapy and $27.04 for CBT compared with community referral. Conclusions: Effective treatment for depression in low-income minority women reduces depressive symptoms but increases costs compared with community referral. The pharmacotherapy and CBT interventions were costeffective relative to community referral for the health care system.
AB - Background: Few clinical trials have evaluated interventions for major depressive disorder in samples of low-income minority women, and little is known about the cost-effectiveness of depression interventions for this population. Objective: To evaluate the cost-effectiveness of pharmacotherapy or cognitive behavior therapy (CBT) compared with community referral for major depression in low-income minority women. Design, Setting, and Participants: A randomized clinical trial was conducted in 267 women with current major depression. Interventions: Participants were randomly assigned to pharmacotherapy (paroxetine hydrochloride or bupropion hydrochloride) (n=88), CBT (n=90), or community referral (n=89). Main Outcome Measures: The main outcomes were intervention and health care costs, depression-free days, and quality-adjusted life years based on Hamilton Depression Rating Scale scores and Medical Outcomes Study 36-Item Short-Form Health Survey summary scores for 12 months. Cost-effectiveness ratios were estimated to compare incremental patient outcomes with incremental costs for pharmacotherapy relative to community referral and for CBT relative to community referral. Results: Compared with the community referral group, the pharmacotherapy group had significantly lower adjusted mean Hamilton Depression Rating Scale scores from the 3rd month through the 10th month (P=.04 to P<.001) of the study, and the CBT group had significantly lower adjusted mean scores from the 5th month through the 10th month (P=.03 to P=.049). There were significantly more depression-free days in the pharmacotherapy group (mean, 39.7; 95% confidence interval, 12.9-66.5) and the CBT group (mean, 25.80; 95% confidence interval, 0.04-51.50) than in the community referral group. The cost per additional depression-free day was $24.65 for pharmacotherapy and $27.04 for CBT compared with community referral. Conclusions: Effective treatment for depression in low-income minority women reduces depressive symptoms but increases costs compared with community referral. The pharmacotherapy and CBT interventions were costeffective relative to community referral for the health care system.
UR - http://www.scopus.com/inward/record.url?scp=23744454327&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=23744454327&partnerID=8YFLogxK
U2 - 10.1001/archpsyc.62.8.868
DO - 10.1001/archpsyc.62.8.868
M3 - Article
C2 - 16061764
AN - SCOPUS:23744454327
SN - 2168-622X
VL - 62
SP - 868
EP - 875
JO - JAMA Psychiatry
JF - JAMA Psychiatry
IS - 8
ER -